LE WE PMID CA
Multiple sclerosis1857Multiple Sklerose

Alemtuzumab ttCD52

Alzheimer s disease

Antiinflammatory compounds

Apolipoprotein E

Atacicept ttBlys ttAPRIL

Autoantibodies Anti CCP

BG 12

CD38

Cladribine

CNS (Astrocyte)

CNS (MRS)

CNS (MRT)

CNS (Stroke BASKET)

Complement system

Cyclophosphamide

Daclizumab ttIL2R

Dalfampridine

Demyelinization

Devic neuromyelitis optica

Epilepsy (BASKET)

Eye and orbita (Imaging)

Fingolimod

FTY720

Fumarate

Glatiramer acetate

Histone deacetylase

IDO Indoleamine oxygenase

Immunopharmacology

Interfering diseases

Laquinimod

Liquor puncture

Mitochondria (Dysfunction)

Mitoxantrone

MRS (Method)

Multiple sclerosis

Myasthenia gravis

Myelin basic protein MBP

Myopathy (Inflammatory)

NAD

Natalizumab ttIntegrinalpha4

Neuromyelitis optica

Neuropathy peripheral

Oligoclonal band study

Optic neuritis

PAD2

Parkinson s disease

Progressive multifocal leukoencephalopathy

Regulatory B cell

Regulatory T cell

Rituximab ttCD20

Spasticity

Statin

T cell (gammadelta)

T cell (Th17)

Teriflunomide

TRPV4

Varicella zoster virus

2006  
1
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review.
[16565096] BMJ 332(7546): 875-84 (2006)
2006  
2
Diagnosis and treatment of multiple sclerosis.
[16513709] BMJ 332(7540): 525-7 (2006)
2002  
3
Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
[12390057] Arch Intern Med 162(19): 2161-9 (2002)
1998  
4
Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
[9521220] Arch Intern Med 158(6): 565-73 (1998)
2006  
5
Multiple sclerosis: treating symptoms, and other general medical issues.
[16478042] Cleve Clin J Med 73(2): 177-86 (2006)
2006  
6
Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
[16444920] Cleve Clin J Med 73(1): 91-102 (2006)
2004  
7
The neuropsychiatry of multiple sclerosis.
[15101497] Can J Psychiatry 49(3): 157-63 (2004)
1996  
8
Psychiatric manifestations of multiple sclerosis: a review.
[8884033] Can J Psychiatry 41(7): 441-5 (1996)
2009  
9
Review of teriflunomide and its potential in the treatment of multiple sclerosis.
[19557143] Neuropsychiatr Dis Treat 5(-): 333-40 (2009)
2008  
10
Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis.
[18728744] Neuropsychiatr Dis Treat 4(2): 321-36 (2008)
2007  
11
Glatiramer acetate in the treatment of multiple sclerosis.
[19300558] Neuropsychiatr Dis Treat 3(2): 259-67 (2007)
2006  
12
The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.
[17015227] Neuron 52(1): 61-76 (2006)
2003  
13
Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
[12797954] Neuron 38(5): 685-8 (2003)
2007  
14
The extracellular matrix in multiple sclerosis pathology.
[17854386] J Neurochem 103(4): 1293-301 (2007)
2007  
15
Multiple sclerosis: a battle between destruction and repair.
[17101032] J Neurochem 100(2): 295-306 (2007)
2007  
16
Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.
[17726912] Dialogues Clin Neurosci 9(2): 125-39 (2007)
2007  
17
Glatiramer acetate in multiple sclerosis: a review.
[17627671] CNS Drug Rev 13(2): 178-91 (2007)
2007  
18
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.
[17461891] CNS Drug Rev 13(1): 79-95 (2007)
2003  
19
Treatments for spasticity and pain in multiple sclerosis: a systematic review.
[14636486] Health Technol Assess 7(40): iii, ix-x, 1-111 (2003)
1993  
20
Epidemiologic evidence for multiple sclerosis as an infection.
[8269393] Clin Microbiol Rev 6(4): 382-427 (1993)
1999  
21
The cellular immunology of multiple sclerosis.
[10204572] J Leukoc Biol 65(4): 444-52 (1999)
2007  
22
The immunological basis for treatment of multiple sclerosis.
[17850581] Scand J Immunol 66(4): 374-82 (2007)
2009  
23
Complement in multiple sclerosis: its role in disease and potential as a biomarker.
[19040603] Clin Exp Immunol 155(2): 128-39 (2009)
2008  
24
Myelin repair: the role of stem and precursor cells in multiple sclerosis.
[17282989] Philos Trans R Soc Lond B Biol Sci 363(1489): 171-83 (2008)
1999  
25
Therapeutic strategies in multiple sclerosis. II. Long-term repair.
[10603622] Philos Trans R Soc Lond B Biol Sci 354(1390): 1711-20 (1999)
1999  
26
Therapeutic strategies in multiple sclerosis. I. Immunotherapy.
[10603621] Philos Trans R Soc Lond B Biol Sci 354(1390): 1697-710 (1999)
1999  
27
Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis.
[10603620] Philos Trans R Soc Lond B Biol Sci 354(1390): 1687-95 (1999)
1999  
28
Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
[10603619] Philos Trans R Soc Lond B Biol Sci 354(1390): 1675-86 (1999)
1999  
29
The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease.
[10603618] Philos Trans R Soc Lond B Biol Sci 354(1390): 1649-73 (1999)
1999  
30
1999  
31
The pathology of multiple sclerosis and its evolution.
[10603616] Philos Trans R Soc Lond B Biol Sci 354(1390): 1635-40 (1999)
1999  
32
1999  
33
Multiple sclerosis: the disease and its manifestations.
[10603614] Philos Trans R Soc Lond B Biol Sci 354(1390): 1615-22 (1999)
2006  
34
Tumor-like multiple sclerosis: report of four cases and literature review.
[17260503] Tumori 92(6): 559-62 (2006)
2006  
35
Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
[16401734] Arch Neurol 63(1): 25-33 (2006)
2005  
36
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
[16216934] Arch Neurol 62(10): 1519-30 (2005)
2005  
37
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.
[16157741] Arch Neurol 62(9): 1345-56 (2005)
2005  
38
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.
[15956157] Arch Neurol 62(6): 865-70 (2005)
2005  
39
Glatiramer acetate therapy: the plot thickens.
[15956155] Arch Neurol 62(6): 858-9 (2005)
2005  
40
Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker.
[15642847] Arch Neurol 62(1): 33-6 (2005)
2002  
41
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.
[12135961] Brain 125(Pt 8): 1676-95 (2002)
1998  
42
The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
[9549485] Brain 121 ( Pt 1)(-): 3-24 (1998)
1997  
43
Primary progressive multiple sclerosis.
[9217691] Brain 120 ( Pt 6)(-): 1085-96 (1997)
2004  
44
Multiple sclerosis: etiological mechanisms and future directions.
[14709772] Exp Biol Med (Maywood) 229(1): 12-20 (2004)
2004  
45
2005  
46
Developing therapeutics for the treatment of multiple sclerosis.
[16489371] NeuroRx 2(4): 638-49 (2005)
2005  
47
Imaging of multiple sclerosis: role in neurotherapeutics.
[15897951] NeuroRx 2(2): 277-303 (2005)
2005  
48
Multiple sclerosis: diagnosis and the management of acute relapses.
[15879043] Postgrad Med J 81(955): 302-8 (2005)
1992  
49
Multiple sclerosis: the impact of MR imaging.
[1546605] AJR Am J Roentgenol 158(4): 849-57 (1992)
1991  
50
Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy.
[1927795] AJR Am J Roentgenol 157(5): 1073-8 (1991)
2009  
51
Tissue-specific MR imaging in multiple sclerosis.
[19617445] AJNR Am J Neuroradiol 30(7): 1277-8 (2009)
2007  
52
Diffusion MR imaging in multiple sclerosis: technical aspects and challenges.
[17353305] AJNR Am J Neuroradiol 28(3): 411-20 (2007)
2006  
53
Multiple sclerosis: the role of MR imaging.
[16775258] AJNR Am J Neuroradiol 27(6): 1165-76 (2006)
2006  
54
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.
[16484429] AJNR Am J Neuroradiol 27(2): 455-61 (2006)
2005  
55
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.
[15760868] AJNR Am J Neuroradiol 26(3): 572-7 (2005)
2002  
56
Diffusion tensor MR imaging of gray matter in different multiple sclerosis phenotypes.
[12063212] AJNR Am J Neuroradiol 23(6): 899-900 (2002)
1998  
57
1998  
58
Investigating multiple sclerosis with spectroscopic imaging: harbinger of a new paradigm.
[9672000] AJNR Am J Neuroradiol 19(6): 1002-3 (1998)
2010  
59
MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.
[20044503] AJNR Am J Neuroradiol 31(7): 1171-7 (2010)
2010  
60
Dirty-appearing white matter: a disregarded entity in multiple sclerosis.
[19833799] AJNR Am J Neuroradiol 31(3): 390-1 (2010)
2010  
61
2010  
62
Cognitive deficits in multiple sclerosis: a systematic review.
[20730323] Arq Neuropsiquiatr 68(4): 632-41 (2010)
2011  
63
Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
[21895607] ASN Neuro 3(4): - (2011)
2010  
64
The role of natalizumab in the treatment of multiple sclerosis.
[20615052] Am J Manag Care 16(6 Suppl): S164-70 (2010)
2011  
65
Guidelines and best practices for appropriate use of dalfampridine in managed care populations.
[21761954] Am J Manag Care 17 Suppl 5 Improving(-): S154-60 (2011)
2010  
66
Is multiple sclerosis a mitochondrial disease?
[19607913] Biochim Biophys Acta 1802(1): 66-79 (2010)
2009  
67
Optic neuritis and risk of MS: differential diagnosis and management.
[19258465] Cleve Clin J Med 76(3): 181-90 (2009)
2009  
68
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
[19814729] Br J Pharmacol 158(5): 1173-82 (2009)
2008  
69
Astrocytes in multiple sclerosis: a product of their environment.
[18516496] Cell Mol Life Sci 65(17): 2702-20 (2008)
2008  
70
Value of oligoclonal band study in clinically isolated syndromes and multiple sclerosis.
[18759537] Expert Rev Neurother 8(9): 1279-80 (2008)
2008  
71
Epstein-Barr virus in the development of multiple sclerosis.
[18345964] Expert Rev Neurother 8(3): 331-3 (2008)
2007  
72
Autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
[17597968] Ann Acad Med Singapore 36(6): 421-6 (2007)
2010  
73
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.
[20682002] Clin Exp Immunol 162(1): 1-11 (2010)
2010  
74
The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.
[20613949] Clin Dev Immunol 2010(-): 186813 (2010)
2009  
75
Genetics and pathogenesis of multiple sclerosis.
[19775910] Semin Immunol 21(6): 328-33 (2009)
2011  
76
The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.
[21373721] Mol Med 17(5-6): 442-7 (2011)
2011  
77
Development of oral immunomodulatory agents in the management of multiple sclerosis.
[21625416] Drug Des Devel Ther 5(-): 255-74 (2011)
2010  
78
New approaches in the management of multiple sclerosis.
[21151622] Drug Des Devel Ther 4(-): 343-66 (2010)
2010  
79
Acute disseminated encephalomyelitis and multiple sclerosis.
[20129937] Brain 133(Pt 2): 317-9 (2010)
2005  
80
Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?
[15975943] Brain 128(Pt 8): 1747-63 (2005)
2006  
81
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.
[16632554] Brain 129(Pt 8): 1953-71 (2006)
2010  
82
Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models.
[20647413] Dis Model Mech 3(9-10): 535-9 (2010)
2011  
83
Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.
[21573085] Neuropsychiatr Dis Treat 7(-): 229-39 (2011)
2011  
84
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.
[21931494] Neuropsychiatr Dis Treat 7(-): 519-27 (2011)
2010  
85
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
[20837848] Arch Neurol 67(9): 1062-7 (2010)
2009  
86
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
[19433659] Arch Neurol 66(5): 593-9 (2009)
2009  
87
Emerging therapies for relapsing multiple sclerosis.
[19597083] Arch Neurol 66(7): 821-8 (2009)
2012  
88
Stimulation of transient receptor potential vanilloid 4 channel suppresses abnormal activation of microglia induced by lipopolysaccharide.
[22331560] Glia 60(5): 761-70 (2012)
2010  
89
Atacicept: targeting B cells in multiple sclerosis.
[21179612] Ther Adv Neurol Disord 3(4): 205-16 (2010)
2011  
90
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.
[21694816] Ther Adv Neurol Disord 4(3): 139-68 (2011)
2011  
91
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination.
[22010041] Ther Adv Neurol Disord 4(5): 281-96 (2011)
2011  
92
Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
[22010043] Ther Adv Neurol Disord 4(5): 319-32 (2011)
2010  
93
Practical considerations on the use of rituximab in autoimmune neurological disorders.
[21179602] Ther Adv Neurol Disord 3(2): 93-105 (2010)
2008  
94
Innovative monoclonal antibody therapies in multiple sclerosis.
[21180564] Ther Adv Neurol Disord 1(1): 43-52 (2008)
2008  
95
Escalating immunotherapy of multiple sclerosis.
[21180576] Ther Adv Neurol Disord 1(3): 181-92 (2008)
2009  
96
Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.
[21180630] Ther Adv Neurol Disord 2(6): 50-61 (2009)
2009  
97
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
[21180619] Ther Adv Neurol Disord 2(5): 291-7 (2009)
2010  
98
Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.
[21124072] MAbs 2(6): 670-81 (2010)
2009  
99
Promising treatments of tomorrow for multiple sclerosis.
[20182576] Ann Indian Acad Neurol 12(4): 283-90 (2009)
2009  
100
Disease-modifying agents in multiple sclerosis.
[20182575] Ann Indian Acad Neurol 12(4): 273-82 (2009)
2009  
101
Management of acute exacerbations in multiple sclerosis.
[20182574] Ann Indian Acad Neurol 12(4): 264-72 (2009)
2009  
102
Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.
[20182573] Ann Indian Acad Neurol 12(4): 254-63 (2009)
2009  
103
Cerebrospinal fluid in multiple sclerosis.
[20182572] Ann Indian Acad Neurol 12(4): 246-53 (2009)
2009  
104
Neuromyelitis optica - an update: 2007-2009.
[20182570] Ann Indian Acad Neurol 12(4): 231-7 (2009)
2009  
105
The importance of NAD in multiple sclerosis.
[19149604] Curr Pharm Des 15(1): 64-99 (2009)
2007  
106
Emerging oral therapies for multiple sclerosis.
[17784852] Int J Clin Pract 61(11): 1922-30 (2007)
2008  
107
Interferons and natalizumab for multiple sclerosis.
[21289915] GMS Health Technol Assess 4(-): Doc09 (2008)
2010  
108
Diffusion imaging in multiple sclerosis: research and clinical implications.
[20882528] NMR Biomed 23(7): 865-72 (2010)
2011  
109
Varicella zoster virus and relapsing remitting multiple sclerosis.
[22096629] Mult Scler Int 2011(-): 214763 (2011)
2011  
110
Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.
[22096630] Mult Scler Int 2011(-): 219049 (2011)
2011  
111
Potential impact of B cells on T cell function in multiple sclerosis.
[22096636] Mult Scler Int 2011(-): 423971 (2011)
2011  
112
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?
[22096641] Mult Scler Int 2011(-): 724871 (2011)
2008  
113
Review: Mitochondria and disease progression in multiple sclerosis.
[19076696] Neuropathol Appl Neurobiol 34(6): 577-89 (2008)
2010  
114
Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
[20061941] Clin Neuropharmacol 33(2): 91-101 (2010)
2009  
115
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management.
[19739692] CNS Drugs 23(10): 805-15 (2009)
2008  
116
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.
[18930111] Prog Neurobiol 86(4): 368-78 (2008)
2008  
117
Multiple sclerosis, cannabinoids, and cognition.
[18305283] J Neuropsychiatry Clin Neurosci 20(1): 36-51 (2008)
2010  
118
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
[20439849] Neurology 74(18): 1463-70 (2010)
2009  
119
Cyclophosphamide therapy in pediatric multiple sclerosis.
[19439723] Neurology 72(24): 2076-82 (2009)
2007  
120
Psychiatric issues in multiple sclerosis.
[17938046] Psychiatr Clin North Am 30(4): 803-17 (2007)
2009  
121
Clinical implications of a possible role of vitamin D in multiple sclerosis.
[19399382] J Neurol 256(9): 1468-79 (2009)
2010  
122
Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.
[19904613] J Neuroimmune Pharmacol 5(2): 176-88 (2010)
2010  
123
Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis.
[20107924] J Neuroimmune Pharmacol 5(2): 189-97 (2010)
2010  
124
Studies in the modulation of experimental autoimmune encephalomyelitis.
[20401539] J Neuroimmune Pharmacol 5(2): 168-75 (2010)
2009  
125
Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.
[19255856] J Neuroimmune Pharmacol 4(2): 249-59 (2009)
2010  
126
Role of the innate immune system in the pathogenesis of multiple sclerosis.
[19931190] J Neuroimmunol 221(1-2): 7-14 (2010)
2007  
127
Control of experimental autoimmune encephalomyelitis by CD4+ suppressor T cells: peripheral versus in situ immunoregulation.
[17900707] J Neuroimmunol 191(1-2): 61-9 (2007)
2007  
128
The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis.
[17916388] J Neuroimmunol 191(1-2): 51-60 (2007)
2007  
129
Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.
[17196667] J Neuroimmunol 184(1-2): 37-44 (2007)
2009  
130
Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
[19577811] J Neuroimmunol 213(1-2): 3-11 (2009)
2007  
131
The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis.
[17031564] Neurochem Res 32(2): 251-6 (2007)
2009  
132
Proton magnetic resonance spectroscopy in multiple sclerosis.
[19064199] Neuroimaging Clin N Am 19(1): 45-58 (2009)
2010  
133
Th17 cells in autoimmune demyelinating disease.
[20195867] Semin Immunopathol 32(1): 71-7 (2010)
2009  
134
Regulatory CD4+CD25high T cells, activated CD4+CD25highCD127high T cells and multiple sclerosis.
[20477058] Expert Rev Clin Immunol 5(2): 115-7 (2009)
2009  
135
Parasite immunomodulation in autoimmune disease: focus on multiple sclerosis.
[20477636] Expert Rev Clin Immunol 5(5): 487-9 (2009)
2008  
136
Autoantibodies and neurodegeneration in multiple sclerosis.
[18521063] Lab Invest 88(8): 796-807 (2008)
2010  
137
The role of dendritic cells in CNS autoimmunity.
[20217033] J Mol Med (Berl) 88(6): 535-44 (2010)
2009  
138
The contribution of gammadelta T cells to the pathogenesis of EAE and MS.
[19199938] Curr Mol Med 9(1): 15-22 (2009)
2008  
139
Multiple sclerosis and regulatory T cells.
[18763026] J Clin Immunol 28(6): 697-706 (2008)
2009  
140
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.
[19707422] Biologics 3(-): 369-76 (2009)
2010  
141
2010  
142
Hematopoietic SCT for the treatment of multiple sclerosis.
[20697363] Bone Marrow Transplant 45(12): 1671-81 (2010)
2011  
143
A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
[21145597] J Neuroimmunol 230(1-2): 1-9 (2011)
2010  
144
miRNAs in multiple sclerosis: regulating the regulators.
[20888650] J Neuroimmunol 229(1-2): 3-4 (2010)
2011  
145
Natalizumab for relapsing-remitting multiple sclerosis.
[21193250] Neurologia 26(6): 357-68 (2011)
2010  
146
Optical coherence tomography (OCT) in optic neuritis and multiple sclerosis.
[20605617] Rev Neurol (Paris) 166(12): 978-86 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Multiple Sklerose im Kindesalter
  • Multiple Sklerose, Diagnostik und Therapie


  • Search PubMed and many other databases on the combined search terms

    GG: multiple sclerosis

  • Multiple Sklerose

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia